The correlation between the incidence of GVHD and the number of infused CD34 þ cells remains controversial for PBSC transplantation after a reduced-intensity-conditioning (RIC) regimen. We evaluated 99 patients transplanted with an HLA-identical sibling after the same RIC (2-Gy-TBI/fludarabine). Donor and recipient characteristics, donor's blood G-CSF-mobilized CD34 þ cell count, and number of infused CD34 þ and CD3 þ cells were analyzed as risk factors for acute and chronic GVHD There was a trend for an increased incidence of extensive chronic GVHD in the quartile of patients receiving more than 10 Â 10 6 CD34 þ cells/kg (P ¼ 0.05). Interestingly, the number of donor's blood CD34 þ cells at day 5 of G-CSF mobilization was closely associated with the incidence of extensive chronic GVHD, that is, 48% (95% CI: 28-68) at 24-months in the quartile of patients whose donors had the highest CD34 þ cell counts versus 24.3% (95% CI: 14-34) in the other patients (P ¼ 0.007). In multivariate analysis, the only factor correlating with extensive chronic GVHD (cGVHD) was the donor's blood CD34 þ cell count after G-CSF (HR 2.49; 95% CI: 1.16-5.35, P ¼ 0.019). This study shows that the incidence of cGVHD is more strongly associated with the donor's ability to mobilize CD34 þ cells than with the number of infused CD34 þ cells.
INTRODUCTION
G-CSF-mobilized PBSC are increasingly used instead of BM cells for allogeneic transplantation because they provide faster engraftment and better survival in recipients with poor-risk disease. 1 As PBSC also reduce the risk of graft failure, they are almost always used in the setting of transplants after RIC regimens. However, PBSC transplantation is associated with a possibly higher incidence of extensive and treatment-resistant chronic GVHD (cGVHD). [1] [2] [3] [4] [5] As cGVHD remains a significant problem after PBSC transplant, a major issue is to identify associated risk factors. Currently, there is no evidence that the factors commonly associated with GVHD after BM transplants have a role in the setting of PBSC transplant. [6] [7] [8] [9] [10] [11] Furthermore, in contrast to results obtained after BM transplants, several studies, mainly in myeloablative PBSC transplantation from HLA identical sibling donors, demonstrated that the number of infused CD34 þ cells strongly impacts the incidence of acute or chronic GVHD in PBSC transplant; 6, 7, [12] [13] [14] however, in the case of PBSC transplantation after RIC, the data remain controversial. [15] [16] [17] [18] [19] [20] In this setting, the heterogeneity of conditioning regimens and donor sources, including HLA identical sibling donor but also unrelated donors, could explain why opposite conclusions have been reported in previous studies.
In this study, we chose to evaluate the risk factors for GVHD in a patient population who received HLA-identical sibling transplants performed after the same RIC consisting of 2-Gy-TBI and fludarabine.
METHODS Patients
This retrospective study took advantage of the registry of the Société Franc¸aise de Greffe de Moelle et de Thérapie Cellulaire. The patients and donors gave prior informed consent for future analysis of their data. All consecutive patients included in the study underwent a first sibling non-myeloablative allogeneic PBSC transplant after a conditioning regimen consisting of 2-Gy-TBI with fludarabine, 21 and were transplanted from a donor who received 10 mg/kg per day of G-CSF for hematopoietic stem cell mobilization. Postgraft immunosuppression therapy consisted of mycophenolate mofetil and cyclosporin. Transplants with HLA-mismatched related or unrelated donor and monozygote twin were excluded, as were ex vivo T-cell-depleted transplants. Transplants with no available data on the infused CD34 þ cell þ cell count in the peripheral blood on day 5 of G-CSF administration were also excluded from the study.
Ninety-nine patients from 13 institutions, transplanted between January 2000 and November 2003, were ultimately included. They were classified as having early or advanced disease. Early disease included chronic myelogenous leukemia in chronic phase, acute leukemia in first CR, refractory anemia without excess blasts, multiple myeloma in first response, chronic lymphocytic leukemia, and Hodgkin's and non-Hodgkin's lymphoma in first or second remission. Acute and chronic GVHD were diagnosed on clinical and/or histological grounds, as previously reported. 22, 23 The characteristics of the 99 patients and their donors are summarized in Table 1 .
PBSC collection and cell subset measurements
Depending on the transplant center, cytapheresis began on day 4 or 5 after the first G-CSF administration. Harvests were performed with a continuous-flow blood separator, most often the Cobe Spectra (Cobe Laboratories, Lakewood, CO, USA), and all cytapheresis products were monitored by the CD34 þ cell counts. The donor CD34 þ cell count determined at day 5 after G-CSF was used for the analysis of risk factors for GVHD, whatever the day of the onset of cytapheresis.
Immunophenotyping was done as recommended by the guidelines of the International Society of Hematotherapy and Graft Engineering. Briefly, double staining with CD45-FITC and with the viability marker CD34-phycoerythrin, 24, 25 and non-specific binding with appropriate isotypic controls were assessed by flow cytometry. Gates were adjusted to eliminate cellular debris from the analysis, and at least 75 000 events were recorded for each sample. The percentage of CD34 þ cells was determined on the basis of side and forward angle light scatter and CD45 and CD34 staining. CD3 þ cell counts were determined using standard procedures of flow cytometry analysis. All the laboratories participated in a quality control program overseen by the French health authorities, ensuring homogeneity between centers and reproducibility.
Pooled cytapheresis products were used for infusion. When possible, the minimum target dose was 4 Â 10 6 CD34 þ cells/kg recipient body weight. The maximum CD34 þ cell dose infused varied between centers, as a number of them limited the number of CD34 þ to 8 or 10 Â 10 6 cells/kg recipient body weight, doses that are considered by some as the threshold associated with a higher risk of GVHD. 6, 12, 13 Statistical analysis
The following endpoints were analyzed: OS, PFS, TRM, progression and incidence of aGVHD and cGVHD. Probabilities of OS and PFS were estimated from the time of transplant using Kaplan-Meier product-limit estimates, whereas the probabilities of TRM, disease progression and GVHD were calculated using cumulative incidence estimates. Acute and chronic GVHD were analyzed as time to event, with relapse and death without GVHD as competing events. For PFS, TRM was considered as a competing risk event.
We used the Fine and Gray proportional hazards regression model of competing risks to identify factors predictive of aGVHD and cGVHD. The Fine and Gray model is a multivariable time-to-event model, which takes into account the fact that individuals can only have one of the two competing events. The model also allows for censoring those individuals who do not have an event during follow-up. Potential prognostic factors are listed in Table 2 . To determine the association of GVHD rates with continuously measured co-variables, patients were grouped into quartiles based on covariate values (CD34 þ or CD3 þ infused cell doses and donor's blood CD34
þ cell count at day 5 after G-CSF). Univariate predictors with P-values of p0.05 were included in a stepwise multivariable regression model. Spearman's rank correlation coefficient was used to estimate the correlation between infused CD34 þ cell dose and donor blood CD34 þ cell count after G-CSF mobilization. We used R (R Foundation for Statistical Computing, Vienna, Austria; www.r-project.org) and its cmprsk package for survival analyses.
RESULTS

Composition of graft and donor mobilized CD34
þ cell counts Table 2 shows the quartile distribution of the total number of CD34 þ and CD3 þ cells in the graft and the donor blood CD34 þ counts at day 5 of G-CSF administration. The median number of CD34 þ cells in donor blood on day 5 of G-CSF administration was 67/mL (range 9-210/ml). The median infused CD34 þ and CD3 þ cell doses per kg of recipient body weight were 6.4 Â 10 6 (range 1.3-22.6) and 282 Â 10 6 (range 88-839), respectively. Thirty patients received more than 8 Â 10 6 CD34 þ /kg and 24 (that is approximatively a quartile) more than 10 Â 10 6 CD34 þ /kg.
Post-transplant outcomes
With a median follow-up of 73 months for survivors, the estimated 5-year OS and PFS rates were 44.5% (95% CI: 35.6-55.7) and 37.7% (95% CI: 29.1-48.7), respectively. The 24-month cumulative incidence rates of progression and TRM were 31% (95% CI: 22; 41) and 15.1% (95% CI: 11; 19.1), respectively. Fifty seven patients have died during the study period. Fifteen died of hematological disease relapse, 9 of GVHD, 6 of fungal infection, 3 of hemorrhage, 2 of acute respiratory distress, 2 of multi-organ failure, and 6 of other transplant-related causes. In 12 cases, the cause of death was unknown.
The incidence rates of grade II-IV aGVHD and grade III-IV aGVHD on day 100 were 34.4% (95% CI: 29.4-39.4) and 9.9% (95% CI: 6.9-12.9), respectively. Seven patients who died before day þ 100 were not evaluable for cGVHD (2 of them received grafts from donors with very good ability to mobilize CD34 þ cell after G-CSF (higher quartile), none of these seven patients received more than 10 Â 10 6 CD34/kg). Fifty eight patients presented a cGVHD, which was limited in 24 cases and extensive in 34 cases. Among these patients, the onset of cGVHD was de novo in 35 cases, quiescent in 9 cases and progressive in 14 cases. The 24-month cumulative incidence rates of all types of cGVHD and of extensive cGVHD were 50.5% (95% CI: 41-60) and 30.3% (95% CI: 21-39), respectively.
Univariate analysis of the risk factors for GVHD: impact of the infused CD34
þ cell doses and of donor blood mobilized CD34 þ cell counts Neither doses of infused CD34 þ and CD3 þ cells nor donor blood CD34 þ cell counts after G-CSF mobilization or patients' or donors' characteristics correlated with the incidence of aGVHD. In contrast, there was a trend for an association between the incidence of extensive cGVHD and the infused CD34 þ cell dose by univariate analysis. In the quartile of patients receiving more than 10 Â 10 6
CD34
þ cells/kg, the incidence of extensive cGVHD at 24 months was 48% (95% CI: 27-69) versus 25% (95% CI: 15.2-34.8) in the other three quartiles (P ¼ 0.05). The incidence of extensive cGVHD was independent of the number of CD3 þ cells infused (Table 2 ). When the impact of the number of G-CSF-mobilized CD34 þ cells in donor blood was evaluated, the count at day 5 after G-CSF was closely associated with the incidence of cGVHD; the incidence of extensive cGVHD at 24 months was 48% (95%CI: 28-68) in the quartile of patients whose donors had the highest CD34 þ cell counts versus 24.3% (95%CI: in the three other quartiles grouped together (P ¼ 0.007) ( Figure 1 ). As expected, the CD34 þ cell dose and the donor blood CD34 þ cell count after G-CSF mobilization were statistically correlated (Po0.001), but the strength of the association was low (Spearman's coefficient R ¼ 0.6). No other factor was associated with the risk of extensive cGVHD by univariate analysis (Table 3 ).
Multivariate analysis of risk factors of extensive cGVHD When including the infused CD34
þ cell doses and the donor mobilized CD34
þ cell counts at day 5 of G-CSF in multivariate analyses, the only factor remaining associated with the incidence of extensive cGVHD was the donor mobilized CD34 þ cell counts (hazards ratio associated with the highest quartile: HR: 2.49 (95% CI: 1.15-5.36, P ¼ 0.019).
DISCUSSION
The impact of the dose of infused CD34
þ cells on GVHD has been studied by several groups after allogeneic PBSC transplant. Most of these studies involved myeloablative transplants with a HLA identical sibling. They show that the dose of infused CD34 þ cells is closely associated with the incidence of GVHD, 6, 7, [12] [13] [14] which led to the recommendation that the dose of CD34 þ cells be limited to þ cell count on day 5 of G-CSF stem cell mobilization: the incidence of extensive cGVHD in the quartile of patients transplanted from a donor with more than 10 6 CD34 þ cell/ mL of blood was compared with that in the three other quartiles of patients. a CML in chronic phase, acute leukemia in first CR, refractory anemia without excess of blasts, multiple myeloma in first response, CLL, Hodgkin's and non-Hodgkin's lymphoma in first or second response.
b Data not available in 13 patients.
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/kg recipient body weight. However, a recent analysis of 2350 PBSC transplants, including different conditioning regimens and both related and unrelated donors, did not confirm these results. 26 Thus, the link between the CD34 þ cell dose and the incidence of GVHD remains unclear in the settings of unrelated transplant and after RIC regimens as reported in other series. [15] [16] [17] [18] [19] [20] 26 These conflicting results may be explained by the heterogeneity of the conditioning regimens, which would lead to different degrees of myeloablation and inflammatory reactions, both playing a major role in the occurrence of GVHD. For these reasons, we chose to evaluate the impact of the CD34 þ cell dose on GVHD in a homogeneous population with regard to the origin of the donor and the type of non-myeloablative conditioning regimen, which consisted of 2-GY-TBI and fludarabine.
On the basis of the studies mentioned above, we compared the incidence of GVHD in the quartile of patients who received the highest dose of infused CD34
þ cells with that in the three other quartiles grouped together. Our data show that the higher risk of extensive cGVHD was associated with the quartile of patients who received more than 10 Â 10 6 CD34 þ cells/kg recipient body weight. This confirms data from previous studies where the highest quartile was the threshold the most significantly associated with an increase in GVHD incidence, and usually corresponded to an infused CD34 þ cell dose between 8 to 10 Â 10 6 CD34 þ cells/kg recipient body weight. 6, 7, 15, 27 We found no correlation between the CD3 þ cell dose infused and the incidence of GVHD, which is consistent with others reports. 6, 7, 12, 13, 15, 17 G-CSF mobilization not only results in higher T-cell numbers, but it also alters significantly the T-cell distribution (Th1, Th2, Treg) and the number and phenotype of B cells and dendritic cells, thereby producing a graft with different characteristics than BM grafts. 28, 29 The impact on GVHD of the dose of different lymphocytes sub-types has been more extensively studied in some reports with contradictory results. Heimfeld et al. reported a higher incidence of cGVHD after related RIC transplantations with higher doses of CD4 þ cells, but others did not find such association. 7, 30, 31 Thus, establishing a clear link between the cell composition of the graft and the incidence of GVHD will require further studies.
As CD34 þ cells have no direct role in allo-responses, the mechanisms underlying the association between CD34 þ cell dose and incidence of GVHD are unclear. The infused CD34 þ cell dose depends closely on the donor response to G-CSF. For that reason, we decided to evaluate the impact on GVHD of the number of donor blood CD34 þ cells after G-CSF mobilization, a parameter strongly associated with the CD34 þ cell dose but not usually evaluated as a risk factor of GVHD. We show that the number of donor blood CD34 þ cells after G-CSF mobilization correlated better with cGVHD than did the dose of infused CD34 þ cells. The mechanisms underlying the relationship between the donor's mobilized CD34 þ cell count and the risk of GVHD remains to be elucidated. CD34
þ cell mobilization by G-CSF is a complex process in which chemokines have a key role. [32] [33] [34] In the healthy population, there is heterogeneity in the ability to mobilize CD34 þ cells after G-CSF, as shown by the large variability of the CD34 þ cell blood count after G-CSF administration (Table 1 ). In fact, 10 to 20% of donors are considered as poor mobilizers. The factors determining poor or 'outstanding' mobilization are poorly defined, although some studies stress the impact of age, sex, weight or ethnicity. [35] [36] [37] [38] [39] [40] In our previous study, the blood counts before G-CSF, including total leukocytes, and neutrophil, monocyte and lymphocyte counts, were not correlated with the donor blood CD34 þ cell count after G-CSF mobilization. 7 SDF-1 is a major chemokine involved in the mobilization process. Its plasma level and the expression of its receptor CXCR-4 on CD34 + cells have been reported to have an impact on G-CSF-mobilized CD34
þ cell blood count in autologous transplants. 41 Chemokines have also a major influence on the occurrence of GVHD through the recruitment of effector cells. [42] [43] [44] We previously studied 58 donors for genetic polymorphisms of SDF-1 and IL-8, two cytokines having a major role in G-CSF-mediated CD34 þ cell mobilization and in lymphocyte migration. However, in this small cohort, we did not find any correlation between SDF-1 and IL-8 genetic polymorphism and transplant outcomes (unpublished data). Further studies identifying the chemokines involved in G-CSFinduced CD34
þ cell mobilization and in lymphocyte migration might shed some light on the relationship between the donor response to G-CSF and the occurrence of GVHD.
In conclusion, this study shows that the incidence of cGVHD is strongly associated with the donor's ability to mobilize CD34 þ cells, suggesting that the donor's responsiveness to G-CSF may have a more critical role than the dose of CD34 þ cells infused per se. Therefore, the donor mobilized CD34 þ cell count may be a useful indicator for predicting the risk of GVHD, as deleterious alloreactive potential is higher with grafts from outstanding mobilizers, regardless of recipient characteristics. Independently of the underlying mechanism, this may have direct implications for post-transplant recipient management, especially with respect to GVHD prophylaxis.
